Transgene SA
TRGNF
$0.85
-$0.15-15.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 79.70K | 80.10K | -- | -- | 18.70K |
| Total Other Revenue | 1.45M | 1.46M | 2.60M | 2.41M | 1.58M |
| Total Revenue | 1.53M | 1.54M | 2.60M | 2.41M | 1.60M |
| Cost of Revenue | 9.30M | 9.34M | 10.16M | 9.42M | 10.05M |
| Gross Profit | -7.77M | -7.81M | -7.56M | -7.01M | -8.45M |
| SG&A Expenses | 2.05M | 2.06M | 2.15M | 1.99M | 1.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 649.60K | 652.40K | -30.60K | -28.40K | 52.20K |
| Total Operating Expenses | 12.01M | 12.06M | 12.28M | 11.39M | 11.81M |
| Operating Income | -10.48M | -10.52M | -9.68M | -8.98M | -10.21M |
| Income Before Tax | -10.61M | -10.66M | -10.95M | -10.15M | -9.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.61M | -10.66M | -10.95M | -10.15M | -9.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.61M | -10.66M | -10.95M | -10.15M | -9.32M |
| EBIT | -10.48M | -10.52M | -9.68M | -8.98M | -10.21M |
| EBITDA | -10.08M | -10.13M | -9.31M | -8.63M | -9.85M |
| EPS Basic | -0.07 | -0.07 | -0.08 | -0.08 | -0.07 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.05 | -0.05 | -0.04 |
| EPS Diluted | -0.07 | -0.07 | -0.09 | -0.08 | -0.07 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.05 | -0.05 | -0.04 |
| Average Basic Shares Outstanding | 156.55M | 156.55M | 132.51M | 132.51M | 132.38M |
| Average Diluted Shares Outstanding | 156.55M | 156.55M | 132.51M | 132.51M | 132.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |